Skip to main content
Top
Published in: Diagnostic Pathology 1/2017

Open Access 01-12-2017 | Research

Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma

Authors: Cristiano Claudino Oliveira, Helena Maciel-Guerra, Luan Kucko, Eric Jun Hirama, Américo Delgado Brilhante, Francisco Carlos Quevedo, Isabela Werneck da Cunha, Fernando Augusto Soares, Ligia Niero-Melo, Patrícia Pintor dos Reis, Maria Aparecida Custodio Domingues

Published in: Diagnostic Pathology | Issue 1/2017

Login to get access

Abstract

Background

Double-hit lymphomas (DHL) are rare high-grade neoplasms characterized by two translocations: one involving the gene MYC and another involving genes BCL2 or BCL6, whose diagnosis depends on cytogenetic examination. This research studied DHL and morphological and/or immunophenotypic factors associated with the detection of these translocations in a group of high-grade non-Hodgkin lymphoma cases.

Method

Clinical and morphological reviews of 120 cases diagnosed with diffuse large B-cell lymphoma and Burkitt lymphoma were conducted. Immunohistochemistry (CD20, CD79a, PAX5, CD10, Bcl6, Bcl2, MUM1, TDT and Myc) and fluorescence in situ hybridization for detection of MYC, BCL2 and BCL6 gene translocations were performed in a tissue microarray platform.

Results

Three cases of DHL were detected: two with translocations of MYC and BCL2 and one with translocations of MYC and BCL6, all leading to death in less than six months. Among 90 cytogenetically evaluable biopsies, associations were determined between immunohistochemistry and fluorescence in situ hybridization for MYC (p = 0.036) and BCL2 (p = 0.001). However, these showed only regular agreement, indicated by Kappa values of 0.23 [0.0;0.49] and 0.35 [0.13;0.56], respectively. “Starry sky” morphology was strongly associated with MYC positivity (p = 0.01). The detection of three cases of DHL, all resulting in death, confirms the rarity and aggressiveness of this neoplasm.

Conclusions

The “starry sky” morphological pattern and immunohistochemical expression of Myc and Bcl2 represent possible selection factors for additional cytogenetic diagnostic testing.
Literature
1.
go back to reference Jaffe E, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008;112(12):4384–6.CrossRefPubMedPubMedCentral Jaffe E, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008;112(12):4384–6.CrossRefPubMedPubMedCentral
2.
go back to reference Hasserjian RP, Ponz BO, Ott G, Elenitoba-Johnson SK, Leval L. Commentary on the WHO classification of tumors of lymphoid tissues (2008): “Gray zone” lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma. J Hematop. 2009;2(2):89–95.CrossRefPubMedPubMedCentral Hasserjian RP, Ponz BO, Ott G, Elenitoba-Johnson SK, Leval L. Commentary on the WHO classification of tumors of lymphoid tissues (2008): “Gray zone” lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma. J Hematop. 2009;2(2):89–95.CrossRefPubMedPubMedCentral
3.
go back to reference Harris NL, Campo E, Jaffe ES, et al. Introduction to the WHO classification of tumors of haematopoietic na lymphoid tissues. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and lymphoid tussues, vol. 2. Lyon: IARC; 2008. p. 14–5. Harris NL, Campo E, Jaffe ES, et al. Introduction to the WHO classification of tumors of haematopoietic na lymphoid tissues. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and lymphoid tussues, vol. 2. Lyon: IARC; 2008. p. 14–5.
4.
go back to reference Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;17(8):2319–3.CrossRef Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;17(8):2319–3.CrossRef
5.
go back to reference Salaverria I, Siebert R. The gray zone between Burkitt’s lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol. 2011;29(14):1835–43.CrossRefPubMed Salaverria I, Siebert R. The gray zone between Burkitt’s lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol. 2011;29(14):1835–43.CrossRefPubMed
6.
go back to reference Zhao XF. Pitfalls in diagnostic hematopathology: part II. Int J Clin Exp Pathol. 2009;3(1):39–46.PubMed Zhao XF. Pitfalls in diagnostic hematopathology: part II. Int J Clin Exp Pathol. 2009;3(1):39–46.PubMed
7.
go back to reference Zhang B, Calado DP, Pasqualucci L, Rajewsky K. An oncogenic role for alteranative NF-κβ signaling in DLBCL revealed upon deregulated BCL6 expression. Cell Rep. 2015;11:715–26.CrossRefPubMedPubMedCentral Zhang B, Calado DP, Pasqualucci L, Rajewsky K. An oncogenic role for alteranative NF-κβ signaling in DLBCL revealed upon deregulated BCL6 expression. Cell Rep. 2015;11:715–26.CrossRefPubMedPubMedCentral
8.
go back to reference Tanaka H, Hashimoto S, Abe D, Sakai S, Takagi T. Double-hit Lymphoma at second relapse of Burkitt-lke Lymphoma: a case report. J Clin Exp Hematop. 2011;51(1):43–7.CrossRefPubMed Tanaka H, Hashimoto S, Abe D, Sakai S, Takagi T. Double-hit Lymphoma at second relapse of Burkitt-lke Lymphoma: a case report. J Clin Exp Hematop. 2011;51(1):43–7.CrossRefPubMed
9.
go back to reference Kluin PM, Harris NL, Stein H, Leoncini L, Raphäel M, Campo E, et al. B-cell lymphoma, unclassificable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tussues, vol. 2. 4th ed. Lyon: IARC; 2008. p. 265. Kluin PM, Harris NL, Stein H, Leoncini L, Raphäel M, Campo E, et al. B-cell lymphoma, unclassificable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tussues, vol. 2. 4th ed. Lyon: IARC; 2008. p. 265.
10.
go back to reference Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34(3):327–40.CrossRefPubMedPubMedCentral Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34(3):327–40.CrossRefPubMedPubMedCentral
11.
go back to reference Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92(9):3151–62. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92(9):3151–62.
12.
go back to reference Li S, Lin P, Young KH, Kanagal-Shamanna R, Yin CC, Medeiros LJ. MYC/BCL2 Double-Hit high-grade B-cell lymphoma. Adv Anat Pathol. 2013;20:315–26.CrossRefPubMed Li S, Lin P, Young KH, Kanagal-Shamanna R, Yin CC, Medeiros LJ. MYC/BCL2 Double-Hit high-grade B-cell lymphoma. Adv Anat Pathol. 2013;20:315–26.CrossRefPubMed
13.
go back to reference Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.CrossRefPubMed Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.CrossRefPubMed
14.
go back to reference Smith SM, Anastasi J, Cohen KS, Godley LA. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. Blood Cells Mol Dis. 2010;45(4):317–23.CrossRefPubMed Smith SM, Anastasi J, Cohen KS, Godley LA. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. Blood Cells Mol Dis. 2010;45(4):317–23.CrossRefPubMed
15.
go back to reference Kawamoto K, Miyoshi H, Yoshida N, Nakamura N, Oshima K, Sone H, et al. MYC translocation and/or BCL2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma. Cancer Sci. 2016;107:853–61.CrossRefPubMedPubMedCentral Kawamoto K, Miyoshi H, Yoshida N, Nakamura N, Oshima K, Sone H, et al. MYC translocation and/or BCL2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma. Cancer Sci. 2016;107:853–61.CrossRefPubMedPubMedCentral
16.
go back to reference Landsburg DJ, Nasta SD, Svoboda J, Morrissette JJD, Schuster SJ. Double-hit cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. Br J Hematol. 2014;166:169–74.CrossRef Landsburg DJ, Nasta SD, Svoboda J, Morrissette JJD, Schuster SJ. Double-hit cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. Br J Hematol. 2014;166:169–74.CrossRef
17.
18.
go back to reference Zhang XM, Aguillera N. New immunohistochemistry for B-cell lymphoma and Hodgkin lymphoma. Arch Pathol Lab Med. 2014;138(12):1666–72.CrossRefPubMed Zhang XM, Aguillera N. New immunohistochemistry for B-cell lymphoma and Hodgkin lymphoma. Arch Pathol Lab Med. 2014;138(12):1666–72.CrossRefPubMed
19.
go back to reference Ventura RA, Martin-Subero JI, Jone M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abdnormalities in routine paraffin-embedded tissue. JMD. 2006;8(2):141–51.PubMedPubMedCentral Ventura RA, Martin-Subero JI, Jone M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abdnormalities in routine paraffin-embedded tissue. JMD. 2006;8(2):141–51.PubMedPubMedCentral
20.
go back to reference Aukema SM, Kreuz M, Kohler CW, et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014;99(4):726–35.CrossRefPubMedPubMedCentral Aukema SM, Kreuz M, Kohler CW, et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014;99(4):726–35.CrossRefPubMedPubMedCentral
21.
go back to reference Oki Y, Noorani M, Lin P, et al. Double-hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Hematol. 2014;166:891–901.CrossRef Oki Y, Noorani M, Lin P, et al. Double-hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Hematol. 2014;166:891–901.CrossRef
22.
go back to reference Swerdlow SH. Update on the WHO classification of malignant lymphomas. Pathology. 2014;46(S2):06. Swerdlow SH. Update on the WHO classification of malignant lymphomas. Pathology. 2014;46(S2):06.
23.
go back to reference Swerdlow SH. Diagnosis of ‘double-hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Hematology Am Soc Hematol Educ Program. 2014;5(1):90–9. Swerdlow SH. Diagnosis of ‘double-hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Hematology Am Soc Hematol Educ Program. 2014;5(1):90–9.
24.
go back to reference Perry AM, Alvarado-Bernal Y, Laurini JA, et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Hematol. 2014;165:382–91.CrossRef Perry AM, Alvarado-Bernal Y, Laurini JA, et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Hematol. 2014;165:382–91.CrossRef
25.
go back to reference Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. J Clin Oncol. 2012;30:3460–67.CrossRefPubMed Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. J Clin Oncol. 2012;30:3460–67.CrossRefPubMed
26.
go back to reference Yan L-X, Liu Y-H, Luo D-L, et al. MYC expression in concert with BCL2 and BCL6 expression predictis outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified. PLoS One. 2014;9(8):e104068.CrossRefPubMedPubMedCentral Yan L-X, Liu Y-H, Luo D-L, et al. MYC expression in concert with BCL2 and BCL6 expression predictis outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified. PLoS One. 2014;9(8):e104068.CrossRefPubMedPubMedCentral
27.
go back to reference Mahmound AZ, George TI, Czuchlewski DR, et al. Scoring of MYC protein expression in diffuse large B-cell lymphomas: concordance rate among hematopathologistis. Mod Pathol. 2015;28(4):545–51.CrossRef Mahmound AZ, George TI, Czuchlewski DR, et al. Scoring of MYC protein expression in diffuse large B-cell lymphomas: concordance rate among hematopathologistis. Mod Pathol. 2015;28(4):545–51.CrossRef
28.
go back to reference Mation-Kalaw E, Tan LHC, Tay K, et al. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations? Histopathology. 2012;61:1214–18.CrossRef Mation-Kalaw E, Tan LHC, Tay K, et al. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations? Histopathology. 2012;61:1214–18.CrossRef
Metadata
Title
Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma
Authors
Cristiano Claudino Oliveira
Helena Maciel-Guerra
Luan Kucko
Eric Jun Hirama
Américo Delgado Brilhante
Francisco Carlos Quevedo
Isabela Werneck da Cunha
Fernando Augusto Soares
Ligia Niero-Melo
Patrícia Pintor dos Reis
Maria Aparecida Custodio Domingues
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2017
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-016-0593-0

Other articles of this Issue 1/2017

Diagnostic Pathology 1/2017 Go to the issue